The New VA/DoD Obesity Guideline in 2026: Semaglutide and Tirzepatide Get the Strongest Recommendation Yet

The Department of Veterans Affairs and the Department of Defense jointly publish clinical practice guidelines that steer care for millions of veterans and active-duty servicemembers. The stakes are high: according to the guideline synopsis, roughly 78% of veterans and 68% of servicemembers are classified as overweight or obese.

Because the VA/DoD process reviews the full body of evidence and grades every recommendation by strength, these guidelines tend to influence care far outside the military system — including how private insurers, employers, and primary care doctors think about obesity treatment. When a system this large and this cost-conscious concludes that two medications deserve the strongest possible endorsement, that is a meaningful signal for every patient considering treatment.

The headline finding is simple. Among all weight-management medications, only semaglutide (the active ingredient in Wegovy and Ozempic) and tirzepatide (the active ingredient in Zepbound and Mounjaro) received the guideline's strongest recommendation — and that endorsement covers both initial weight loss and long-term weight maintenance, always paired with lifestyle changes.

Older medications were graded noticeably lower. Phentermine-topiramate, liraglutide, and naltrexone-bupropion received weaker ("suggest") recommendations, and the panel found the evidence insufficient to recommend for or against orlistat, metformin, and SGLT2 inhibitors for weight loss.

For patients, that ranking matters. If you have been offered an older, cheaper medication first, the most rigorous recent evidence review in the country says the GLP-1 class — and especially tirzepatide and semaglutide — is where the strongest proof of benefit sits. If you want a deeper comparison of how the two stack up against each other, see our breakdown of Zepbound vs Wegovy HD.

Perhaps the most practically important line in the document: the panel suggests against discontinuing weight-management medication once it is working. The official VA patient summary is blunt about why — weight is easily regained after stopping, and long-term use, while it may not keep producing new weight loss, helps maintain results and prevent rebound.

This reframes obesity treatment the way clinicians already treat high blood pressure or high cholesterol: as a chronic condition managed over time, not a short course of pills. The same summary notes that if you are not losing weight after 3 to 4 months, or you regain a significant amount, the right move is usually adjusting the dose or switching medications with your provider — not abandoning treatment.

If cost or side effects have you considering stopping anyway, talk to your provider about a plan first. We have covered what the evidence says about maintaining weight loss after stopping a GLP-1 — it is possible, but it takes structure.

The guideline also updates how obesity itself is identified. BMI stays as a screening tool, but clinicians are now urged to add a waist-based measure. A waist of 40 inches or more in men or 35 inches or more in women signals clinically concerning obesity, with lower cutoffs for patients of Asian descent, and a waist-to-height ratio of 0.50 or higher serves the same flag.

That change could matter a great deal if your BMI sits near a treatment threshold. Someone with a "borderline" BMI but significant abdominal fat — the pattern most tied to metabolic disease — may now qualify for treatment that a BMI-only rule would have denied. Curious whether you would qualify under current criteria? Our guide to GLP-1 eligibility walks through the requirements.

No medication got a free pass. Every drug recommendation in the guideline is tied to a comprehensive lifestyle intervention: structured changes to eating, activity, and habits with ongoing support from a care team, aiming for an initial 5-10% body-weight loss. Notably for anyone managing care from home, the guideline supports delivering that intervention by phone or video, not just in person — a recognition that remote programs can produce real results.

That is exactly the model modern telehealth weight-loss care is built on: medication where the evidence supports it, plus continuous check-ins, dose adjustments, and side-effect management between visits rather than at a once-a-year appointment.

A few practical takeaways from the new guidance. First, if you have obesity — by BMI or now by waist measure — asking about semaglutide or tirzepatide is asking for the option with the strongest evidence grade, not a shortcut. Second, go in planning for the long term: budget, insurance, and expectations should all assume ongoing treatment, because the guideline explicitly warns against stopping once it works. Third, common side effects are still real — nausea, vomiting, constipation, and diarrhea are the most frequent with GLP-1 medications, usually worst during dose increases — and these medications are not appropriate for everyone, including people with a personal or family history of medullary thyroid carcinoma or MEN2, or during pregnancy. A licensed provider should screen for these before any prescription, and decisions about starting, adjusting, or stopping should always be made together with that provider.

If the new guideline has you thinking seriously about treatment, JoeyMed makes the evidence-backed path simple. Start with an online consultation at JoeyMed Weight Loss — a licensed provider reviews your health history, screens for contraindications, and determines whether GLP-1 therapy fits your situation. Patients who qualify can access options like high-dose tirzepatide (Tirz HD), with anti-nausea support available to manage the most common side effects during titration. And because the guideline treats obesity care as long-term care, JoeyMed's model is built around ongoing provider check-ins and dose adjustments — not a one-time prescription. Explore JoeyMed's wellness programs to see how weight management fits into your bigger health picture.